Levodopa improves motor deficits but can further disrupt cognition in a macaque parkinson model

Movement Disorders

Volumn 28, Issue 5, 2013, Pages 663-667

  Schneider, Jay S ^a   Pioli, Elsa Y ^b   Jianzhong, Yang ^b   Li, Qin ^b   Bezard, Erwan ^b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b Williams House   (United Kingdom)

^c INSTITUT DES MALADIES NEURODÉGÉNÉRATIVES   (France)

Author keywords

Cognition; Levodopa; Motor; MPTP; Primate

Indexed keywords

BENSERAZIDE PLUS LEVODOPA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE TITRATION; LOW DRUG DOSE; MACACA; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANALYSIS OF VARIANCE; ANIMALS; ANTIPARKINSON AGENTS; COGNITION DISORDERS; CONDITIONING, OPERANT; DISEASE MODELS, ANIMAL; LEVODOPA; MACACA FASCICULARIS; MALE; MOVEMENT; MPTP POISONING; PHOTIC STIMULATION; TIME FACTORS;

EID: 84877926437     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25258     Document Type: Article

References (21)

1. Brown RG, Marsden CD. Cognitive function in Parkinson's disease: from description to theory. Trends Neurosci 1990;13:21-29.
2. Sawamoto N, Honda M, Hanakawa T, Fukuyama H, Shibasaki H. Cognitive slowing in Parkinson's disease: a behavioral evaluation independent of motor slowing. J Neurosci 2002;22:5198-5203.
3. Hietanen M, Teravainen H. Cognitive performance in early Parkinson's disease. Acta Neurol Scand 1986;73:151-159.
4. Levin BE, Llabre MM, Weiner WJ. Cognitive impairments associated with early Parkinson's disease. Neurology 1989;39:557-561.
5. Owen AM, James M, Leigh PN, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992;115:1727-1751.
6. Verbaan D, Marinus J, Visser M, et al. Cognitive impairment in Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:1182-1187.
7. Cools R, Barker RA, Sahakian BJ, Robbins TW. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001;11:1136-1143.
8. Cools R, Lewis SJG, Clark L, Barker RA, Robbins TW. L-dopa disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 2007;32:180-189.
9. Schneider JS, Kovelowski CJ. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 1990;519:122-128.
10. Decamp E, Schneider JS. Attention and executive function deficits in chronic low dose MPTP-treated non-human primates. Eur J Neurosci 2004;20:1371-1378.
11. Schneider JS, Van Velson M, Menzaghi F, Lloyd GK. Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment. Ann Neurol 1998;43:311-317.
12. Schneider JS, Tinker JP, Menzaghi F, Lloyd GK. The subtype-selective nicotinic acetylcholine receptor agonist SIB-1553A improves both attention and memory components of a spatial working memory task in chronic low dose 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-treated monkeys. J Pharm Exp Ther 2003;306:401-406.
13. Decamp E, Schneider JS. Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model. Brain Res 2009;1262:109-114.
14. Schneider JS, Gonczi H, Decamp E. Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom progression onset and/or duration of symptoms. Brain Res 2003;990:38-44.
15. Lewis SJG, Dove A, Robbins TW, Barker RA, Owen AM. Striatal contributions to working memory: a functional magnetic resonance imaging study in humans. Eur J Neurosci 2004;19:755-760.
16. Owen AM. Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 2004;10:525-537.
17. Lewis SJ, Slabosz A, Robbins TW, Barker RA, Owen AM. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson;s disease. Neuropsychologia 2005;43:823-832.
18. Kulisevsky J. Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease. Drugs Aging 2000;16:365-379.
19. Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;67:53-83.
20. Williams SM, Goldman-Rakic PS. Widespread origin of the primate mesofrontal dopamine system. Cereb Cortex 1998;8:321-345.
21. Nieoullon A, Coquerel A. Dopamine: a key regulator to adapt action, emotion, motivation, and cognition. Curr Opin Neurol 2003;16:S3-S9.